StockNews.AI

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidance, and Amends Earnout Terms with Exact Sciences

StockNews.AI • 12 hours

EXASTMO
High Materiality8/10

Information

MDxHealth Reports Preliminary Fourth Quarter and Full Year 2025 Revenues, Issues 2026 Revenue Guidan...

Original source

AI Summary

MDxHealth expects 2025 revenues of $109 million, up 21%. 2026 revenue guidance set at $137-140 million, representing 26-28% growth. Company integrated Exosome business, resulting in 128% growth in liquid-based units. Earnout payment to Exact Sciences extended; warrants issued for shares. CEO expresses confidence in sustainable growth and EBITDA margin improvement.

Sentiment Rationale

MDXH's significant revenue growth and positive outlook indicate strong performance. Historical examples show that strong revenue growth often leads to stock price appreciation.

Trading Thesis

The forecasted revenue and EBITDA growth suggest sustained positive impact over several quarters, similar to previous growth trajectories of biotech firms that successfully integrate acquisitions.

Market-Moving

  • MDxHealth expects 2025 revenues of $109 million, up 21%.
  • 2026 revenue guidance set at $137-140 million, representing 26-28% growth.
  • Company integrated Exosome business, resulting in 128% growth in liquid-based units.

Key Facts

  • MDxHealth expects 2025 revenues of $109 million, up 21%.
  • 2026 revenue guidance set at $137-140 million, representing 26-28% growth.
  • Company integrated Exosome business, resulting in 128% growth in liquid-based units.
  • Earnout payment to Exact Sciences extended; warrants issued for shares.
  • CEO expresses confidence in sustainable growth and EBITDA margin improvement.

Companies Mentioned

  • EXAS (EXAS)
  • TMO (TMO)

Corporate Developments

The article details MDXH's financial growth and strategic steps, indicating a strong probability of influencing market sentiment and investor decisions.

MDxHealth Reports Strong Preliminary Q4 and Full Year 2025 Revenues

IRVINE, CA – January 12, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, has released its preliminary financial results for the fourth quarter and the full year of 2025, along with its revenue guidance for 2026. The financial report highlights significant year-over-year growth, reflecting the company's successful execution of its growth strategies.

Preliminary Financial Results for 2025

MDxHealth anticipates reporting fourth quarter revenues of approximately $30.5 million and full-year revenues of around $109 million. This represents an impressive year-over-year growth of 23% for Q4 and 21% for the full year.

In terms of product units sold during Q4, the company billed:

  • 11,201 tissue-based units (5% decrease YoY)
  • 27,486 liquid-based units (128% increase YoY)

This growth is attributed to MDxHealth's focus on integrating the Exosome Diagnostics business and successfully converting Select mdx customers to ExoDx.

For the entire year, the company billed:

  • 49,180 tissue-based units (18% increase YoY)
  • 71,920 liquid-based units (57% increase YoY)

As of the end of 2025, MDxHealth reported a cash balance of $29.0 million.

Revenue Guidance for 2026

MDxHealth has issued revenue guidance for 2026, projecting earnings between $137 million and $140 million. This forecast indicates a year-over-year growth rate of 26% to 28%, showcasing the company's confidence in its operational strategies and market positioning.

Amendments to Earnout Terms with Exact Sciences

On January 9, 2026, MDxHealth announced an amendment to the earnout obligation related to its 2022 GPS acquisition from Exact Sciences. The revised agreement stipulates that the remaining earnout payments will be structured as follows:

  • $15.0 million due in 2026
  • $18.0 million due in 2027
  • $21.5 million due in 2028

In exchange, MDxHealth will issue warrants to Exact Sciences for 3 million shares of its common stock with an exercise price of $5.265 per warrant.

CEO's Insights on Growth Strategy

Michael K. McGarrity, CEO of MDxHealth, expressed satisfaction with the company’s growth trajectory, stating, “We are pleased to report continued execution on our growth strategy, with Q4 and 2025 full year revenue growth exceeding 20%.” He emphasized the robust sales channel and expanded offerings that are expected to sustain this growth into 2026, projecting an adjusted EBITDA margin run rate of 10% by year-end.

About MDxHealth

MDxHealth is at the forefront of precision diagnostics, providing actionable molecular information to enhance patient diagnosis and treatment. The company’s innovative tests utilize proprietary genomic, epigenomic, and exosomal technologies to aid in the diagnosis and prognosis of prostate cancer and other urologic diseases.

For more information, visit mdxhealth.com and follow on social media: Twitter, Facebook, and LinkedIn.

Reporting Calendar for 2026

  • February 26, 2026: Full Year 2025 results
  • May 14, 2026: Q1-2026 financial results and business update
  • May 28, 2026: Annual general shareholders’ meeting
  • August 13, 2026: Q2-2026 financial results and business update
  • November 12, 2026: Q3-2026 financial results and business update

Forward-Looking Statements

This release contains forward-looking statements about MDxHealth’s anticipated future performance, involving certain risks and uncertainties. Actual results may differ materially from those projected. For more detailed information on various risks, please refer to the company’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission.

Contact Information

For more information, please contact:
LifeSci Advisors
John Fraunces, Managing Director
Tel: +1 917 355 2395
Email: jfraunces@lifesciadvisors.com

Related News